{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T23:40:04Z","timestamp":1745970004173,"version":"3.40.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40119-013-0013-4","type":"journal-article","created":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T15:15:35Z","timestamp":1362582935000},"page":"57-68","source":"Crossref","is-referenced-by-count":10,"title":["Thrombin Receptor Antagonism in Antiplatelet Therapy"],"prefix":"10.1007","volume":"2","author":[{"given":"C.","family":"Olivier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"13_CR1","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(06)68770-9","volume":"367","author":"AD Lopez","year":"2006","unstructured":"Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747\u201357.","journal-title":"Lancet"},{"key":"13_CR2","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","volume":"357","author":"G Davi","year":"2007","unstructured":"Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482\u201394.","journal-title":"N Engl J Med"},{"key":"13_CR3","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJMra0801082","volume":"359","author":"B Furie","year":"2008","unstructured":"Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938\u201349.","journal-title":"N Engl J Med"},{"key":"13_CR4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","volume":"60","author":"H Jneid","year":"2012","unstructured":"Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF\/AHA focused update of the guideline for the management of patients with unstable angina\/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60:645\u201381.","journal-title":"J Am Coll Cardiol"},{"key":"13_CR5","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569\u2013619.","journal-title":"Eur Heart J"},{"key":"13_CR6","first-page":"2999","volume":"32","author":"F Werf Van de","year":"2009","unstructured":"Van de Werf F, Bax J, Betriu A, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2009;32:2999\u20133054.","journal-title":"Eur Heart J"},{"key":"13_CR7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1160\/TH12-06-0377","volume":"109","author":"D Aradi","year":"2013","unstructured":"Aradi D, Kom\u00f3csi A, Vorobcsuk A, Serebruany VL. Impact of clopidogrel and potent P2Y12-inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention. Systematic review and meta-analysis. Thromb Haemost. 2013;109:93\u2013101.","journal-title":"Thromb Haemost"},{"key":"13_CR8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehp504","volume":"31","author":"DJ Angiolillo","year":"2010","unstructured":"Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010;31:17\u201328.","journal-title":"Eur Heart J"},{"key":"13_CR9","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/eurheartj\/ehq326","volume":"31","author":"KA Fox","year":"2010","unstructured":"Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J. 2010;31:2755\u201364.","journal-title":"Eur Heart J"},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","volume":"49","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1538-7836.2010.03809.x","volume":"8","author":"C Combescure","year":"2010","unstructured":"Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:923\u201333.","journal-title":"J Thromb Haemost"},{"key":"13_CR12","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315.","journal-title":"N Engl J Med"},{"key":"13_CR13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357.","journal-title":"N Engl J Med"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0031-6997(24)01493-5","volume":"53","author":"SR Macfarlane","year":"2001","unstructured":"Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev. 2001;53:245\u201382.","journal-title":"Pharmacol Rev"},{"key":"13_CR15","first-page":"H1962","volume":"267","author":"B Tesfamariam","year":"1994","unstructured":"Tesfamariam B. Thrombin receptor-mediated vascular relaxation differentiated by a receptor antagonist and desensitization. Am J Physiol. 1994;267:H1962\u20137.","journal-title":"Am J Physiol"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/sj.bjp.0703737","volume":"131","author":"DN Derkach","year":"2000","unstructured":"Derkach DN, Ihara E, Hirano K, Nishimura J, Takahashi S, Kanaide H. Thrombin causes endothelium-dependent biphasic regulation of vascular tone in the porcine renal interlobar artery. Br J Pharmacol. 2000;131:1635\u201342.","journal-title":"Br J Pharmacol"},{"key":"13_CR17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00005344-199310000-00015","volume":"22","author":"DD Ku","year":"1993","unstructured":"Ku DD, Zaleski JK. Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. J Cardiovasc Pharmacol. 1993;22:609\u201316.","journal-title":"J Cardiovasc Pharmacol"},{"key":"13_CR18","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","volume":"3","author":"SR Coughlin","year":"2005","unstructured":"Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3:1800\u201314.","journal-title":"J Thromb Haemost"},{"key":"13_CR19","doi-asserted-by":"crossref","first-page":"11189","DOI":"10.1073\/pnas.96.20.11189","volume":"96","author":"H Andersen","year":"1999","unstructured":"Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA. 1999;96:11189\u201393.","journal-title":"Proc Natl Acad Sci USA"},{"key":"13_CR20","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1161\/01.CIR.91.12.2961","volume":"91","author":"JJ Cook","year":"1995","unstructured":"Cook JJ, Sitko GR, Bednar B, et al. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation. 1995;91:2961\u201371.","journal-title":"Circulation"},{"key":"13_CR21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1124\/jpet.102.042663","volume":"304","author":"CK Derian","year":"2003","unstructured":"Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003;304:855\u201361.","journal-title":"J Pharmacol Exp Ther"},{"key":"13_CR22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(03)01973-3","volume":"473","author":"Y Kato","year":"2003","unstructured":"Kato Y, Kita Y, Hirasawa-Taniyama Y, et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol. 2003;473:163\u20139.","journal-title":"Eur J Pharmacol"},{"key":"13_CR23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1073\/pnas.0610188104","volume":"104","author":"ER Vandendries","year":"2007","unstructured":"Vandendries ER, Hamilton JR, Coughlin SR, Furie B, Furie BC. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci USA. 2007;104:288\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"key":"13_CR24","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1517\/13543784.2010.521741","volume":"19","author":"SD Tomasello","year":"2010","unstructured":"Tomasello SD, Angiolillo DJ, Goto S. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events. Expert Opin Investig Drugs. 2010;19:1557\u201367.","journal-title":"Expert Opin Investig Drugs"},{"key":"13_CR25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2011.01.058","volume":"657","author":"M Kogushi","year":"2011","unstructured":"Kogushi M, Matsuoka T, Kawata T, et al. The novel and orally active thrombin receptor antagonist E5555 (atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur J Pharmacol. 2011;657:131\u20137.","journal-title":"Eur J Pharmacol"},{"key":"13_CR26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2011.05.034","volume":"666","author":"M Kogushi","year":"2011","unstructured":"Kogushi M, Matsuoka T, Kuramochi H, et al. Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats. Eur J Pharmacol. 2011;666:158\u201364.","journal-title":"Eur J Pharmacol"},{"key":"13_CR27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1160\/TH08-12-0805","volume":"102","author":"VL Serebruany","year":"2009","unstructured":"Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt D. The in vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost. 2009;102:111\u20139.","journal-title":"Thromb Haemost"},{"issue":"Suppl. 1","key":"13_CR28","first-page":"14","volume":"28","author":"M Takeuchi","year":"2007","unstructured":"Takeuchi M. Pharmacodynamics and safety of a novel protease activated receptor-1 antagonist E5555 for healthy volunteers. Eur Heart J. 2007;28(Suppl. 1):14.","journal-title":"Eur Heart J"},{"key":"13_CR29","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/eurheartj\/ehq320","volume":"31","author":"S Goto","year":"2010","unstructured":"Goto S, Ogawa H, Takeuchi M, et al. Double-blind, placebo-controlled phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J. 2010;31:2601\u201313.","journal-title":"Eur Heart J"},{"key":"13_CR30","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/CIRCULATIONAHA.110.000786","volume":"123","author":"ML O\u2019Donoghue","year":"2011","unstructured":"O\u2019Donoghue ML, Bhatt DL, Wiviott SD, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes Trial. Circulation. 2011;123:1843\u201353.","journal-title":"Circulation"},{"key":"13_CR31","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.001404","volume":"123","author":"SD Wiviott","year":"2011","unstructured":"Wiviott SD, Flather MD, O\u2019Donoghue ML, et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease Trial. Circulation. 2011;123:1854\u201363.","journal-title":"Circulation"},{"key":"13_CR32","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1053\/euhj.2000.2474","volume":"21","author":"SR Mehta","year":"2000","unstructured":"Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21:2033\u201341.","journal-title":"Eur Heart J"},{"key":"13_CR33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","volume":"115","author":"EG Bovill","year":"1991","unstructured":"Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med. 1991;115:256\u201365.","journal-title":"Ann Intern Med"},{"key":"13_CR34","unstructured":"Chintala M, Vemulapalli S, Kurowski S, et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Arterioscler Thromb Vasc Biol. 2008;28:e32\u2013e149 (Abstract P579)."},{"key":"13_CR35","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/jm800180e","volume":"51","author":"S Chackalamannil","year":"2008","unstructured":"Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008;51:3061\u20134.","journal-title":"J Med Chem"},{"key":"13_CR36","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","volume":"373","author":"RC Becker","year":"2009","unstructured":"Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009;373:919\u201328.","journal-title":"Lancet"},{"key":"13_CR37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20\u201333.","journal-title":"N Engl J Med"},{"key":"13_CR38","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404\u201313.","journal-title":"N Engl J Med"},{"key":"13_CR39","doi-asserted-by":"crossref","unstructured":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993:329:673\u201382.","DOI":"10.1056\/NEJM199309023291001"},{"key":"13_CR40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","volume":"76","author":"JH Chesebro","year":"1987","unstructured":"Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76:142\u201354.","journal-title":"Circulation"},{"issue":"335\u201341","key":"13_CR41","first-page":"e3","volume":"158","author":"DA Morrow","year":"2009","unstructured":"Morrow DA, Scirica BM, Fox KA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J. 2009;158(335\u201341):e3.","journal-title":"Am Heart J"},{"key":"13_CR42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","volume":"380","author":"BM Scirica","year":"2012","unstructured":"Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet. 2012;380:1317\u201324.","journal-title":"Lancet"},{"key":"13_CR43","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1161\/CIRCULATIONAHA.112.114496","volume":"126","author":"MP Bonaca","year":"2012","unstructured":"Bonaca MP, Morrow DA, Braunwald E. Vorapaxar for secondary prevention in patients with peripheral artery disease: results from the peripheral artery disease cohort of the TRA2\u00b0P-TIMI 50 Trial. Circulation. 2012;126:520\u20131.","journal-title":"Circulation"},{"key":"13_CR44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5482\/HAMO-12-05-0006","volume":"32","author":"D Duerschmied","year":"2012","unstructured":"Duerschmied D, Bode C. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism? Hamostaseologie. 2012;32:221\u20137.","journal-title":"Hamostaseologie"},{"key":"13_CR45","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood-2012-09-355958","volume":"121","author":"KM Austin","year":"2013","unstructured":"Austin KM, Covic L, Kuliopulos A. Matrix metalloproteases and PAR1 activation. Blood. 2013;121:431\u20139.","journal-title":"Blood"},{"key":"13_CR46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.112.091918","volume":"126","author":"P Zhang","year":"2012","unstructured":"Zhang P, Gruber A, Kasuda S, et al. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation. 2012;126:83\u201391.","journal-title":"Circulation"},{"key":"13_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11239-012-0752-4","volume":"35","author":"S Chatterjee","year":"2013","unstructured":"Chatterjee S, Sharma A, Mukherjee D. PAR-1 antagonists: current state of evidence. J Thromb Thrombolysis. 2013;35:1\u20139.","journal-title":"J Thromb Thrombolysis"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-013-0013-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T23:21:45Z","timestamp":1745968905000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40119-013-0013-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,7]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["13"],"URL":"https:\/\/doi.org\/10.1007\/s40119-013-0013-4","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"type":"print","value":"2193-8261"},{"type":"electronic","value":"2193-6544"}],"subject":[],"published":{"date-parts":[[2013,3,7]]}}}